Patrick Soon-Shiong's ImmunityBio bags FDA approval for Anktiva to challenge Merck in bladder cancer
By Angus Liu
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
US FDA approves ImmunityBio's bladder cancer therapy
By Puyaan Singh & Pratik Jain
FDA Action Alert: ImmunityBio, Aquestive, XOMA and More
By Tristan Manalac
Full Coverage of this story
FDA Advisory Panel Review of Guardant Health's Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
CRC Screening in Primary Care: The Blood Test Option
By Kenneth W Lin
Researchers developing new colon cancer tests amid rising cases
By Chris Martinez
Next-gen testing - The Source
By Terri Nappier
Test that can enhance the likelihood of identifying colorectal cancer produced by Mainz Biomed
By Liza Laws
Full Coverage of this story
FDA recalls Abbott heart pumps linked to deaths, injuries
By Holly Hacker & Daniel Chang
FDA Recalls Heart Pumps Linked to Deaths and Injuries
By Holly Hacker & Daniel Chang
Patients Facing Death Are Opting for a Lifesaving Heart Device — But at What Risk?
By Holly Hacker & Daniel Chang
HeartMate II and 3 LVADs Recalled Due to Potential for Outflow Graft Obstruction
By Caitlin E. Cox
FDA Issues Alert Over Heart Pump Deaths
Full Coverage of this story
Abeona shares tumble as FDA declines to approve skin disorder treatment
By Pratik Jain & Kalluvila Sriraj
Full Coverage of this story
FDA Requires Boxed Warning for Secondary Cancers on CAR-T Therapies
By Tristan Manalac
ImmunityBio Shares Soar Premarket on FDA Nod for Anktiva
By Colin Kellaher
Genentech Wins FDA Approval for First Adjuvant Therapy for ALK-Positive, Early NSCLC
By Tristan Manalac
Roche snags postsurgery FDA nod for Alecensa, eyes even broader lung cancer use
By Angus Liu
Alectinib Significantly Improves Disease-Free Survival in ALK-Positive NSCLC
By Maggie L. Shaw
Roche Drug Scores Label Expansion for Earlier Use in Lung Cancer
By Frank Vinluan
Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion
Full Coverage of this story
Alvotech Signs U.S. Agreement
Full Coverage of this story
Vertex inches closer to acute pain market with FDA application acceptance
By Gabrielle Masson
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
Vertex starts rolling submission for non-opioid pain therapy
By Dulan Lokuwithana
Vertex Pharma scientist talks about the long road to developing non-addictive painkillers
Vertex shares climb as non-opioid pain treatment advances
By Eleanor Laise
Full Coverage of this story
FDA Warns Against Counterfeit Botox in Multiple U.S. States Following Adverse Reactions
New York officials latest to warn against Botox shots from unlicensed providers
By Maya Yang
Suspected counterfeit botox now linked to adverse reactions in 11 states
Fake Botox sickened patients in several states. Here's how to avoid it
By Rachel Treisman
Botched Botox injections sicken at least three people in NYC: What to know about symptoms
Full Coverage of this story
FDA approves Lumicell's fluorescent system for highlighting residual breast cancer tissue
By Conor Hale
Full Coverage of this story
FDA classifies recall of Boston Scientific device as 'most serious'
By Maju Samuel & Christy Santhosh
Full Coverage of this story
What is delta-8 THC and is it safe? FDA gives warning as sales rise
By Alexis Simmerman & Marley Malenfant
Full Coverage of this story
FDA Grants New Indication for Subcutaneous Entyvio
FDA Approves Vedolizumab for Maintenance Therapy to Treat Crohn Disease
By Kennedy Ferruggia
Takeda gets USFDA nod for Entyvio subcutaneous administration for Crohn's disease
By Ruchika Sharma & Kamal Kohli
FDA Approve Takeda's Crohn's Disease Therapy
FDA Approves New Takeda Drug Delivery Option - TipRanks.com
Full Coverage of this story
Past Gift Sparks Future Breakthroughs and FDA Approval
By Jonesa Rodriguez
Most of Lilly's Mounjaro and Zepbound doses in limited supply, FDA says
By Sriparna Roy, Shailesh Kuber & Devika Syamnath
Zepbound weight loss drug shortage has no immediate end in sight, Eli Lilly says
By Berkeley Lovelace, Berkeley Lovelace Jr. & Christine Romans
Weight-loss drugs could see a shortage until 2025, makers predict
Most doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA says
By Annika Kim Constantino
Zepbound shortage: Weight loss drugs’ limited availability to continue, Eli Lilly says
By Alix Martichoux
Full Coverage of this story
FDA requests $7.2bn for FY2025 to unify Human Foods Program, strengthen data infrastructure
By Deniz Ataman
Harris Remarks at FY25 Budget Hearing for the Food and Drug Administration (As Prepared)
FDA Targets 2025 Funds Toward Supply Chain Resiliency
Stakeholders Ask Congress to Approve $214 Million More Than FDA's FY 2025 Budget Request
LIVE: Robert Califf testifies on FDA’s 2025 fiscal year budget in House hearing (Video)
Full Coverage of this story
FDA Greenlights Phase 1 Trial of Narcolepsy Drug Candidate ORX750
Centessa cleared to commence clinical trials of ORX-750 in US
Centessa Pharmaceuticals Advances Narcolepsy Drug Trials - TipRanks.com
Centessa Pharmaceuticals (CNTA) Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
Centessa Gains on New Product News
By Glenn Wilkins
Full Coverage of this story
FDA shifts approach to investigation into lead poisoning outbreak traced to applesauce
By Coral Beach
FDA winds down part of lead-contaminated applesauce probe
By Berkeley Lovelace & Berkeley Lovelace Jr.
Lead Poisoning in children linked to Cinnamon in Apple Sauce
By Bill Marler
Following a wave of lead-spiked applesauce pouches, FDA urges Congress to enforce mandatory testing
By Michael La Corte
FDA head pushes for mandated lead testing by food manufacturers
By Filip Timotija
Full Coverage of this story
FDA Grants Breakthrough Therapy Designation to Ziftomenib in NPM1-Mutant AML
Full Coverage of this story
FDA: ‘Zero sugar’ soda recalled for having ‘full sugar’
By Michael Bartiromo & Aaron Marrie
PepsiCo Recalls Schweppes Zero Sugar Ginger Ale
By Stacey Leasca
‘Zero sugar’ ginger ale recalled for being ‘full-sugar product,’ FDA site says
By Aaron Marrie & Michael Bartiromo
PepsiCo recall: Sugar-free Schweppes Ginger Ale had 'full sugar'
By Amaris Encinas
FDA: Ginger ale recalled in Pennsylvania, other states
By Aaron Marrie
Full Coverage of this story
Congressman Urges FDA on Dietary Supplements
By Erick Mitchell
FDA wants to boost trial innovation with new center at CDER
By Helen Floersh
Full Coverage of this story
FDA Clears AI Tool for Detecting Cancer Signs in Bone Marrow
By Ben Wodecki
Full Coverage of this story
Senators Urge FDA to Crack Down on Social Media Prescription Drug Promotion
By Thomas Sullivan
Full Coverage of this story
Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expect
By Vandana Singh
Corcept Therapeutics (CORT) Reports Positive Results From Open-Label Portion of Phase 3 GRACE Trial
Corcept falls on limited data from late-stage trial of Cushing's syndrome drug
Corcept falls after phase 3 results on Cushing's candidate doesn't include some data
By Jonathan Block, MPH
Corcept reports promising phase 3 trial results for Cushing's drug
By Natashya Angelica
Full Coverage of this story
US FDA issues warning letters to retailers against underage sale of ZYN nicotine pouches
By Maju Samuel & Granth Vanaik
Are Zyns bad for you? What the nicotine pouch is made of
By Hannah Yasharoff
Nicotine pouches for your mouth are becoming increasingly popular. Here's why health experts are concerned
By Taylor Nicioli
'Nicotine wakes you up': How Zyn pouches became the US extreme right's latest obsession with regaining 'lost' manhood
By Marita Alonso
FDA Warns Retailers Over Illegal Tobacco Sales
By Angela Hanson
Full Coverage of this story
India’s role in medical product space represents both a unique opportunity and an important responsibility: FDA Commissioner
Full Coverage of this story
Jubilant gets VAI classification from USFDA for Roorkee unit
BREAKING: Jubilant Cadista Closing Manufacturing Operations in Salisbury
By Lauren Miller & Sean Curtis
Jubilant Cadista Pharmaceuticals to close Salisbury manufacturing plant - 47abc
By Sarah Ash
Jubilant Pharmova to get its US generics business back to profitability through these measures
By Hormaz Fatakia
USFDA determines inspection classification of 'Voluntary Action Indicated' for the Solid dosage manufacturing facility at Roorkee, India
Full Coverage of this story
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors
By Vijay Kishore & Christy Santhosh
Abbott's heart valve repair device gains US FDA approval
By Puyaan Singh
Twin Cities researchers lead development on device used as alternative to open-heart surgery
By Ben Henry
Abbott Receives FDA Approval for TriClip™, First-of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve
Ten doctors on FDA panel reviewing Abbott heart device had financial ties with company
By Holly Hacker & David Hilzenrath
Cardiology team performs transcatheter edge-to-edge repair with newly approved device
By Kamal Kohli
Full Coverage of this story
Sun Pharma slips 3% after OAI status from USFDA for Dadra facility
By Deepak Korgaonkar
Sun Pharma At Over Three-Week Low After FDAs Action On Dadra Plant
By Ananya Chaudhuri
Sun Pharmaceutical Industries underperforms Friday when compared to competitors
Sun Pharma shares trade 3.4% lower following US FDA regulatory action
Sun Pharma: 2 key reasons why HSBC expects 16% upside despite regulatory woes
By Ujjval Jauhari
Full Coverage of this story
Import alerts, warning letters, drug recalls — why ‘pharmacy to the world’ is facing US FDA heat
By Sumi Dutta
Full Coverage of this story
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company's Expanding Focus on Cancer Supportive Care
Why Jaguar Health Stock Is Up Today - Jaguar Health (NASDAQ:JAGX)
Burlingame baseball: Will Robbins | | smdailyjournal.com
By Nathan Mollat
What is 'chemo mouth' and could a brand new treatment offer relief?
By Isabel Cameron
Full Coverage of this story
Lupin gains after USFDA concludes inspection at Gujarat facility with no observations
Full Coverage of this story
Some doses of Lilly's Mounjaro in tight supply through April, US FDA says
Desperate users of Ozempic rival Zepbound drive five hours to get weight-loss meds because of shortages
By Ariel Zilber
Weight-loss drug shortage result of 'unprecedented demand'
By Julie Hyman
Weight Loss Drugs Zepbound and Mounjaro Are in Shortage Due to 'Demand Increase,' FDA Says
By Vanessa Etienne
Eli Lilly's Wegovy Competitor Is Causing Supply Constraints: What It Means for the Stock
Full Coverage of this story